A Call For Action: Integrating Payor Requirements Into Phase III Clinical Trials
The biopharma industry is facing a paradigm shift in which pivotal trials, which traditionally address regulatory requirements, must also supply payors with clinically meaningful data - or the industry will continue to struggle with market access and disappointed expectations. Easton Associates foresees a two-step process emerging to address payors' needs.
You may also be interested in...
The biopharma industry invests substantially in post-approval studies to convey information about the value of its products to constituents, but the majority of these efforts do not address core, real-world questions raised by payors. A new business model recognizing the strategic value of medical affairs to market access is needed to stem the tide of disappointing reimbursement decisions.
After several years of either niche or me-too drug launches, 2010 brought an encouraging wave of new molecular entities and novel biologics to market, including several first-in-class drugs addressing large therapeutic areas.